| Objective:To explore the effect of trimodal prehabilitation on clinical efficacy、quality of life、anxiety and depression in patients with non-small cell lung cancer(NSCLC)during the first-line chemotherapy.Methods:A Total of 168 patients with NSCLC were selected from oncology centerof Xuzhou Central Hospital from September 2020 to December 2022,they were randomly divided into observation group(84 cases)and control group(84 cases).The observation group received first-line chemotherapy combined with trimodal prehabilitation treatment,while the control group only received first-line chemotherapy.The clinical effect was compared after treatment,and quality of life was evaluated by FACT-L scale,HADS was used to evaluate anxiety and depression.Results:After two cycles of chemotherapy,the effective rate(CR+PR+SD)of the observation group was 82.1%,slightly higher than 78.6%of the control group,but there was no significant difference.The incidence of nausea and vomiting in the observation group was lower than that in the control group(P<0.05).Using FACT-L scale,the scores of PWB,EWB,FWB and LCS as well as the total score in the observation group were significantly higher than that before treatment(P<0.05),these scores were also higher than that in the control group after treatment,the difference was statistically significant(P<0.05).With respect to anxiety and depression,after 2 cycles of treatment,the HADS-A and HADS-D scores in the observation group were significantly decreased compared with those before treatment(P<0.05),and also significantly decreased compared with the control group(P<0.05).Conclusion:When trimodal prehabilitation is combined with first-line chemotherapy to treat NSCLC patients,it reduces adverse reaction of nausea and vomiting without influencing efficacy.It can improve the scores of PWB,EWB,FWB,LCS,HADS-A and HADS-D and enhance the overall quality of life effectively. |
PDF Full Text Request